Search This Blog

Tuesday, August 9, 2022

T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox

 T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans to explore the potential to develop a rapid molecular diagnostic test for detection of the monkeypox virus, including technical and commercial feasibility. Monkeypox is a rare disease caused by infection with the monkeypox virus that is part of the orthopoxvirus family of viruses, which also contains smallpox. The main symptom of monkeypox is a rash, but individuals may also present with flu like symptoms. A rapid and accurate diagnosis of monkeypox is essential to expedite treatment and to limit exposure and spread of the disease.

https://finance.yahoo.com/news/t2-biosystems-explore-potential-develop-123000590.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.